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It is established that neuronal nitric-oxide synthase
(nNOS) is ubiquitylated and proteasomally degraded.
The proteasomal degradation of nNOS is enhanced by
suicide inactivation of nNOS or by the inhibition of
hsp90, which is a chaperone found in a native complex
with nNOS. In the current study, we have examined
whether CHIP, a chaperone-dependent E3 ubiquitin-
protein isopeptide ligase that is known to ubiquitylate
other hsp90-chaperoned proteins, could act as an ubiq-
uitin ligase for nNOS. We found with the use of HEK293T
or COS-7 cells and transient transfection methods that
CHIP overexpression causes a decrease in immunode-
tectable levels of nNOS. The extent of the loss of nNOS is
dependent on the amount of CHIP cDNA used for trans-
fection. Lactacystin (10 M), a selective proteasome in-
hibitor, attenuates the loss of nNOS in part by causing
the nNOS to be found in a detergent-insoluble form.
Immunoprecipitation of the nNOS and subsequent West-
ern blotting with an anti-ubiquitin IgG shows an in-
crease in nNOS-ubiquitin conjugates because of CHIP.
Moreover, incubation of nNOS with a purified system
containing an E1 ubiquitin-activating enzyme, an E2
ubiquitin carrier protein conjugating enzyme (UbcH5a),
CHIP, glutathione S-transferase-tagged ubiquitin, and
an ATP-generating system leads to the ubiquitylation of
nNOS. The addition of purified hsp70 and hsp40 to this
in vitro system greatly enhances the amount of nNOS-
ubiquitin conjugates, suggesting that CHIP is an E3 li-
gase for nNOS whose action is facilitated by (and possi-
bly requires) its interaction with nNOS-bound hsp70.
Nitric-oxide synthases (NOSs)1 are cytochrome P450-like he-
moprotein enzymes that catalyze the conversion of L-arginine
to citrulline and nitric oxide by a process that requires NADPH
and molecular oxygen. NOS is bidomain in structure with an
oxygenase domain, which contains the cysteine residue that is
coordinated to the prosthetic heme as well as the tetrahydro-
biopterin binding site, and a reductase domain, which contains
the binding sites for FMN, FAD, and NADPH. The NOS is a
highly regulated enzyme requiring homodimerization and as-
sociation with Ca2-calmodulin for activity. Another mecha-
nism for regulation involves the selective ubiquitin-dependent
proteasomal degradation of dysfunctional NOS (1). This is
evident, for example, when metabolism-based or suicide in-
activators cause the covalent alteration and inactivation of
neuronal NOS (nNOS) and trigger enhanced proteasomal deg-
radation of the enzyme (2). The nature of the factor(s) that
selectively recognize dysfunctional nNOS is unknown; how-
ever, inhibition of hsp90 leads to enhanced proteasomal degra-
dation of nNOS, implicating the hsp90-based chaperone ma-
chinery as a potential regulator of nNOS protein levels (3).
Hundreds, perhaps thousands, of cellular proteins are chap-
eroned by the hsp90/hsp70-based chaperone machinery (4), and
it has been proposed that these chaperones play a key role in
protein triage decisions that maintain quality control of cellu-
lar proteins. CHIP is a U-box-containing E3 ubiqutin ligase
that binds through its tetratricopeptide repeat (TPR) domain to
independent TPR acceptor sites on hsp90 and hsp70 (5, 6).
CHIP facilitates the ubiquitylation of chaperone substrates,
including the glucocorticoid receptor (7), the cystic fibrosis
transmembrane conductance regulator protein (8), and Raf-1
kinase (9). Because a substantial fraction of all cellular pro-
teins is degraded by the ubiquitin-proteasome pathway, the
interaction of CHIP with hsp90 and/or hsp70 is an attractive
mechanism for the control of protein triage decisions. The exact
mechanism by which CHIP elicits this action is still unclear,
although at least three general mechanisms have been inves-
tigated: the interaction of CHIP with hsp70 to ubiquitinate
chaperoned proteins (5, 8–10), a displacement of p23 from
hsp90 by CHIP that remodels the hsp90-heterocomplex to favor
degradation (7), and a combination of the hsp70 and hsp90
mechanisms (6, 10).
In the current study we found that CHIP acts to ubiquitylate
nNOS and that hsp70 and hsp40 can facilitate this conjugation
reaction. The transient transfection of CHIP into HEK293T
cells or COS-7 cells causes the loss of nNOS that is partially
attenuated by inhibition of the proteasome with lactacystin.
Immunopurification of nNOS from these cells reveals an in-
creased level of nNOS-ubiquitin conjugates because of CHIP.
Moreover with the use of an in vitro system containing purified
proteins, we show that CHIP in concert with hsp70 and hsp40
effectively ubiquitylates nNOS. This is of special interest in
light of a recent discovery that CHIP causes not the ubiquity-
lation but rather the redistribution of soluble endothelial NO
synthase (eNOS) to an insoluble compartment and impairs
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eNOS trafficking through the Golgi apparatus (11). This differ-
ence of the two enzymes in trafficking versus degradation may
relate to the differences in the structure of the N termini, which
include a PDZ domain in nNOS but not eNOS and myristyla-
tion and palmitylation sites on eNOS but not nNOS.
EXPERIMENTAL PROCEDURES
Materials
Untreated rabbit reticulocyte lysate was from Green Hectares
(Oregon, WI). (6R)-5,6,7,8-Tetrahydro-L-biopterin (BH4) was purchased
from Dr. Schirck’s laboratory (Jona, Switzerland). Protein A-Sepharose,
ubiquitin, ATP, creatine phosphokinase, L-arginine, radicicol, rabbit
polyclonal anti-nNOS, mouse monoclonal anti-GST, and mouse anti-
tubulin were purchased from Sigma. The affinity-purified rabbit IgG
used for Western blotting of nNOS was from Transduction Laboratories
(Lexington, KY), which used C-terminal peptide (residues 1095–1289)
as immunogen. The affinity-purified IgG used for Western blotting and
immunoprecipitation of Ub was from Dako Corp. (Carpinteria, CA). The
rabbit antiserum used to immunoprecipitate nNOS was raised against
rat neuronal NOS and was the generous gift of Dr. Lance Pohl (National
Heart, Lung, and Blood Institute, National Institutes of Health, Be-
thesda, MD). Rabbit anti-CHIP antibody was from Affinity BioReagents
(Golden, CO). The mouse monoclonal anti-c-Myc IgG was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Lactacystin and
MG132 were purchased from Biomol (Plymouth Meeting, PA). The
cDNA for rat neuronal NOS was kindly provided by Dr. Solomon Snyder
(Johns Hopkins Medical School, Baltimore, MD). The cDNA for His-
HA-tagged ubiquitin was from Dr. Yi Sun (University of Michigan).
GST-tagged ubiquitin, ubiquitin aldehyde, ubiquitin-activating enzyme
(E1), and GST-tagged UbcH5a were from Boston Biochem (Cambridge,
MA). Creatine phosphate was from Fluka. Nickel-nitrilotriacetic acid-
agarose was from Qiagen, Inc. (Valencia, CA).
Methods
Cell Culture and Transient Transfection—Human embryonic kidney
(HEK) 293T cells were cultured in minimum essential medium supple-
mented with 10% fetal bovine serum. COS-7 cells were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bo-
vine serum. Transient transfections of 293T or COS-7 cells were carried
out with the use of a standard calcium phosphate method as described
previously (12) in 6-well plates. The rat nNOS cDNA was subcloned
from PVL1393 (3) into the EcoRI and NotI sites of pcDNA3.1. Human
CHIP cDNA and myc-CHIP cDNA was in pcDNA3 (11, 13). Indicated
amounts of CHIP cDNA and nNOS cDNA were transfected into 70–
80% confluent cells such that the total amount of cDNA was kept
constant with vector plasmid. Cells were transfected for 28 h, and
where indicated were treated with lactacystin (10 M) for an additional
20 h. As indicated in experiments where CHIP was immunoprecipi-
tated, myc-CHIP cDNA was used.
SDS-Polyacrylamide Gel Electrophoresis, Western Blotting, and Im-
munoprecipitation—Cells from each well of a 6-well plate were har-
vested 48 h after transfection, washed with ice-cold phosphate-buffered
saline, and homogenized with a TenBroeck ground glass homogenizer
in 0.1 ml of HS buffer (10 mM Hepes, pH 7.4, 0.32 M sucrose, 2 mM
EDTA, 6 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 2
g/ml aprotinin, 10 g/ml trypsin inhibitor, 15 mM sodium vanadate,
1% Nonidet P-40, and 5 mM N-ethylmaleimide). Where indicated, the
transfected cells were treated with 10 M lactacystin or water vehicle
for 20 h before harvesting. In some studies, the transfected cells were
treated with 20 M radicicol or an equivalent amount of Me2SO vehicle
for 24 h before harvesting. Homogenates were centrifuged for 15 min at
16,000  g, and the supernatant was taken as the “soluble” fraction of
cells. The remaining pellet was considered the “insoluble” fraction and
was washed once with phosphate-buffered saline and then sonicated
after the addition of 0.1 ml of HS buffer. An aliquot (60 l) of the
resulting soluble or insoluble sample was added to 40 l of sample
buffer containing 5% SDS, 20% glycerol, 6 mg/ml dithiothreitol, and
0.02% bromphenol blue in 125 mM Tris-HCl, pH 6.8. After boiling, 40 l
of the soluble and insoluble protein samples were resolved on 6%
SDS-polyacrylamide gels and transferred to nitrocellulose membranes
for 2 h at 100 volts. Immunoreactive bands were visualized with the use
of enhanced chemiluminescence reagent (Super Signal, Pierce) and
X-Omat film (Eastman Kodak Co.). In some experiments, the total cell
lysates were prepared by direct sonication in HS buffer and subsequent
boiling in sample buffer. In studies where nNOS or ubiquitin was
immunopurified, the cells were grown in 10-cm plates and transfected
with 6 g of nNOS cDNA, 6 g of His-HA-Ub cDNA, and 0.6 g of CHIP
cDNA. The nNOS was immunoprecipitated from the soluble fraction
with a rabbit polyclonal antibody as described previously (14).
Expression and Purification of nNOS, CHIP, hsp70, and hsp40—Rat
nNOS was expressed in Sf9 insect cells using a recombinant baculovi-
rus and purified by 25-ADP-Sepharose and gel-filtration chromatog-
raphy as described previously (3). Heme was added as an albumin
conjugate during the expression as described (3). His-CHIP was bacte-
rially expressed and purified by nickel-nitrilotriacetic acid affinity chro-
matography as described previously (5). hsp70 was purified from rabbit
reticulocyte lysate by sequential chromatography on DE52, hydroxy-
lapatite, and ATP-agarose as described previously (15). YDJ-1, the
yeast ortholog of hsp40, was expressed in bacteria and purified by
sequential chromatography on DE52 and hydroxylapatite as described
previously (16).
In Vitro Ubiquitylation of nNOS—To conjugate Ub to nNOS, purified
nNOS (0.24 g) was incubated with a purified system containing an E1
ubiquitin-activating enzyme (0.1 M), an E2 GST-tagged UbcH5a (4.0
M), His-tagged CHIP (4.0 M), GST-tagged ubiquitin (8.3 M), 1 mM
dithiothreitol, and an ATP-generating system consisting of 4 mM ATP,
20 mM creatine phosphate, 10 mM MgCl2, and 20 units/ml creatine
phosphokinase, expressed as final concentrations, for 2 h at 30 °C in a
total volume of 20 l of 50 mM Tris-Cl, pH 7.5. After incubation, 20 l
of sample buffer was added, and an aliquot (10 l) was loaded for
Western blotting. In some studies, nNOS was pretreated with hsp70
and hsp40 and then ubiquitylated as above. In these experiments, 5.0
M hsp70 and 0.5 M hsp40 were incubated for 5 min at 30 °C with 1.5
M nNOS and 2.5 l of an ATP-generating system (50 mM ATP, 250 mM
creatine phosphate, 20 mM magnesium acetate, and 100 units/ml crea-
tine phosphokinase) in a total volume of 25 l of 50 mM Hepes, pH 7.5.
The reaction mixture was placed on ice and diluted 5-fold with 10 mM
Hepes buffer, pH 7.4, containing 100 mM KCl, and 5 mM dithiothreitol.
An aliquot (5 l) of this reaction mixture was substituted for nNOS in
the ubiquitylation reaction mixture containing purified ubiquitin li-
gases described above and was probed for ubiquitin conjugation.
RESULTS
CHIP Enhances the Proteasomal Degradation of nNOS in
HEK293T Cells—With the use of transient transfection meth-
ods, we tested to see if CHIP, a known ubiquitin E3 ligase for
some other hsp90-chaperoned proteins, could act to enhance
the ubiquitylation and proteasomal degradation of nNOS. We
have previously used the HEK293 cell system to characterize
the ubiquitylation and proteasomal degradation of nNOS (14).
In this system, both functional inactivation of the nNOS with
suicide inactivators and inhibition of hsp90 enhance the ubiq-
uitin-proteasomal degradation of nNOS (2, 3). HEK293T cells
were transiently transfected with CHIP and nNOS for 48 h,
and cellular lysates were prepared by sonication in detergent-
containing buffer. The amount of nNOS, CHIP, and tubulin in
these lysates was determined by Western blotting. In the ex-
periment shown in Fig. 1, transfection with increasing
amounts of CHIP cDNA decreases the amount of immunode-
tectable nNOS (lanes 1–4). The total amount of cDNA used was
made constant by use of the vector plasmid. Treatment of the
cells with 10 M lactacystin, a highly selective inhibitor of
the proteasome, for the last 20 h of transfection increased the
amount of nNOS observed (lanes 5–8). The bands correspond-
ing to nNOS in all samples were quantified by laser densitom-
etry, and the results are plotted in Fig. 1B. From this analysis,
it is clear that the loss of nNOS caused by CHIP is greatly
diminished by lactacystin (cf. open circles with closed circles),
an indication that CHIP acts to enhance nNOS degradation by
the proteasome.
In light of a recent finding that CHIP directs eNOS to an
insoluble fraction that is not easily extracted by detergent
unless sonicated (11), we chose to investigate the effect of CHIP
on nNOS distribution to a detergent insoluble fraction pre-
pared from cells in a manner similar to that described for
eNOS. HEK293T cells were lysed manually by use of a Ten-
Broeck glass homogenizer in detergent-containing buffer, and
the 16,000  g supernatant (soluble) and pellet (insoluble)
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fractions were prepared. The insoluble fraction was sonicated
and boiled in sample buffer so that this fraction could be ana-
lyzed by Western blotting. As shown in Fig. 2A, CHIP causes a
decrease in the nNOS present in the soluble fraction. Lactacys-
tin had little effect on the soluble nNOS (see samples under
Soluble) unlike that observed for the sonicated cell lysates.
CHIP appears to slightly increase the amount of nNOS present
in the insoluble fraction, whereas a large increase in insoluble
nNOS is found after treatment with lactacystin (Insoluble).
Lactacystin has been shown to cause the accumulation of pro-
teins that are destined for proteasomal removal in an ordered
but aggregated state that is resistant to solubilization by
detergent (17, 18).
In addition to HEK293T cells, we investigated the effect of
CHIP in COS-7 cells (Fig. 2B). CHIP causes a loss of nNOS in
the soluble fraction of COS-7 cells that is partially attenuated
by lactacystin. Lactacystin also causes the accumulation of
nNOS in the insoluble fraction of COS-7 cells. Thus, the de-
crease in nNOS protein caused by CHIP is not unique to the
HEK293T cells.
Effect of Radicicol and CHIP on nNOS—CHIP directly in-
teracts with hsp90 and hsp70, and it is thought that the func-
tional role of CHIP in mediating protein levels are caused by
these interactions (5, 6). To confirm that nNOS is regulated by
chaperones in our cell model, we tested the effect of radicicol, a
specific hsp90 inhibitor, and compared it to the effect of CHIP.
As shown in Fig. 3A, treatment of HEK293T cells with radicicol
alone causes a decrease in the amount of nNOS in the soluble
fraction (cf. lane 1 and lane 4) and greater amounts of nNOS in
the insoluble fraction (cf. lane 7 and lane 10). The loss of nNOS
in the soluble fraction is consistent with our previous observa-
tion after inhibition of hsp90 with geldanamycin (2). The ap-
pearance of nNOS in the insoluble fraction has not been re-
ported previously. To discern the effect of CHIP with radicicol,
the bands corresponding to nNOS in the soluble and insoluble
fractions were quantified by laser densitometry, and the re-
sults are plotted in Fig. 3, B and C, respectively. In the soluble
fraction, CHIP causes the loss of nNOS in both radicicol treated
(solid circles) and untreated cells (open circles) such that at the
highest amount of CHIP similar amounts of nNOS are present.
In the insoluble faction, there is an accumulation of nNOS in
both radicicol-treated (solid circles) and untreated cells (open
circles). Thus, CHIP is able to decrease nNOS in the soluble
fraction and increase it in the insoluble fraction even in the
presence of radicicol. It remains to be shown whether the hsp90
is not fully inhibited by radicicol and CHIP acts on the remain-
ing hsp90 or CHIP causes a further decrease by a process
independent of binding to hsp90. Studies to be described below
suggest that the CHIP interaction with hsp70 is important.
CHIP Enhances the Ubiquitylation of nNOS in HEK293T
Cells—We wanted to obtain direct evidence of the effects of
CHIP on the ubiquitylation of nNOS. The nNOS present in
HEK293T cells was immunopurified and blotted for nNOS and
ubiquitin. The nNOS is specifically precipitated from soluble
fraction of HEK293T cells by the immune (IP) IgG antibody but
not by the non-immune (NI) IgG (Fig. 4 middle panel, cf. lanes
1–4 with lanes 5–8). The nNOS is observed in cells as mono-
and polyubiquitin conjugates (14), and the levels of these con-
jugates are increased after treatment with lactacystin (, cf. lane
5 with lane 6). CHIP acts to increase the level of nNOS-Ub
conjugates with a more pronounced increase in the presence of
lactacystin (lanes 7 and 8). The effect may be underestimated
because of the lower amounts of nNOS immunopurified from
CHIP-transfected cells as well as the finding that most of the
lactacystin-sensitive pool of nNOS ends up in the insoluble
fraction, which is not amenable to the immunopurification
procedure. Interestingly, CHIP is selectively immunoprecipi-
tated by the anti-nNOS antibody (cf. lanes 7 and 8 with lanes 3
and 4), indicating that CHIP exists in a complex with nNOS.
This is expected because nNOS is found in native complexes
with large amounts of hsp70 and small amounts of hsp90 (3),
and CHIP binds to hsp70 and hsp90 through TPR acceptor
sites. The association of nNOS with CHIP and other chaper-
ones is explored in further detail later.
To further validate that nNOS-Ub conjugates have formed,
we immunoprecipitated with anti-ubiquitin and blotted for
nNOS (Fig. 4B). This is important because the Western blot
with anti-ubiquitin above does not differentiate between
nNOS-ubiquitin conjugates and ubiquitin conjugates of pro-
teins associated with nNOS. Several higher molecular mass
nNOS bands were observed after immunoprecipitation with
anti-ubiquitin but not in the non-immune controls. The most
FIG. 1. Lactacystin protects against the CHIP-mediated de-
crease of nNOS protein in HEK293T cells. The effect of CHIP
transfection on nNOS, which was detected in the sonicated cell lysates,
was determined in co-transfection studies of HEK293T cells as de-
scribed under “Experimental Procedures.” CHIP and tubulin levels
were also determined. A, cells were transfected with nNOS (0.1 g) and
different amounts of CHIP cDNA (0, 0.1, 0.5, and 1.0 g) and subse-
quently treated with () or without () 10 M lactacystin. An experi-
ment typical of three independent experiments is shown. B, the band
corresponding to nNOS in A was analyzed by laser densitometry. The
effect of CHIP transfection on nNOS levels without lactacystin (open
circles) or with lactacystin (closed circles) is plotted. The values are the
mean  S.E. (n  3).
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intense signals were observed in samples transfected with
CHIP and treated with lactacystin, consistent with the forma-
tion of nNOS-ubiquitin conjugates.
CHIP Enhances the Ubiquitylation of nNOS in an in Vitro
System Containing Purified Ub Ligases—The ubiquitin ligase
activity of CHIP has been observed in an in vitro system contain-
ing other known components of a ligase system, including puri-
fied E1 and E2 (10, 11, 13). To more definitively assess whether
CHIP is a ubiquitin ligase for nNOS, we utilized a similar in vitro
system containing purified nNOS, E1, E2, and CHIP. We used
GST-tagged ubiquitin so that the conjugates could be more easily
detected by Western blotting with anti-nNOS IgG. As shown in
Fig. 5A in the left panel, nNOS treated with E1, E2, and GST-Ub
gives some faint higher molecular mass nNOS immunoreactive
bands consistent with conjugation with GST-Ub (lane 2). This
may reflect the ability of E2 enzymes to carry out limited ligase
reactions with target proteins even in the absence of E3 ligases
such as CHIP (19). The addition of CHIP to this system greatly
increases the level of ubiquitin conjugates (lane 3). The addition
of purified hsp70 and hsp40 to the CHIP-containing reaction
further enhances the level of nNOS-ubiquitin conjugates (lane 4).
Probing of the same blot with anti-GST also revealed a banding
pattern similar to that for nNOS, although other protein-GST-Ub
conjugates are probably present. As shown in Fig. 5B, our puri-
fied preparation of nNOS contains substantial amounts of insect
hsp70 derived from baculovirus expression in Sf9 cells consistent
with our previous observation (3). This hsp70 co-immunoabsorbs
with nNOS, and thus a portion of nNOS is in complex with this
chaperone (data not shown). Thus, it may be that hsp70 is re-
quired for the binding and action of CHIP and that the lower
levels of conjugate formed in the absence of added hsp70 is
caused by the low levels of hsp70 in our nNOS preparations.
FIG. 2. Effect of CHIP and lactacystin on the accumulation of detergent-resistant nNOS in HEK293T and COS-7 cells. Cells were
treated as described in Fig. 1 except that the samples were homogenized with TenBroeck ground glass homogenizer, and the soluble and insoluble
fractions were prepared and probed for nNOS, CHIP, and -tubulin by Western blotting as described under “Experimental Procedures.” The signal
from samples of the insoluble fraction was much weaker than that of the soluble fraction, and thus the film was exposed for a greater duration for
visualization of the insoluble samples. The cells were transfected with nNOS (1.0 g) and different amounts of CHIP cDNA (0, 0.1, 0.5, and 1.0
g) and subsequently treated with () or without ()10 M lactacystin. A, effect of CHIP and lactacystin on nNOS transfected in HEK293T cells.
An experiment typical of four independent experiments is shown. B, effect of CHIP and lactacystin on nNOS transfected in COS-7 cells. An
experiment typical of three independent experiments is shown.
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nNOS Exists in Heterocomplexes with CHIP and hsp70—We
wanted to address the biochemical interaction between nNOS
and CHIP as well as other chaperones. As shown in Fig. 6A,
immunoprecipitation of nNOS (IP) from lactacystin-treated
cells is accompanied by co-adsorption of hsp70 and CHIP.
These proteins are not observed in the non-immune samples
(NI). Consistent with our earlier report (3), there is a faint
signal for hsp90. As shown in Fig. 6B, anti-myc specifically
immunoprecipitates myc-CHIP (cf. IP with NI). The anti-myc
immunoprecipitates from lactacystin-treated cells contain
nNOS and hsp70 consistent with the finding that CHIP binds
to hsp70 through a TPR acceptor site (5).
DISCUSSION
We have previously shown that hsp90 and hsp70 are associ-
ated with nNOS and that inhibition of hsp90 by geldanamycin
or suicide inactivation of nNOS both lead to enhanced protea-
somal degradation of the enzyme (2, 3, 14). One potential
mechanism that explains these observations of nNOS degrada-
tion is the selective recognition of a dysfunctional form of nNOS
by chaperones that in turn recruit ubiquitin ligases. Because
CHIP is a U-box-containing E3 ubiqutin ligase that binds
through its TPR domain to independent TPR acceptor sites on
hsp90 and hsp70 and mediates ubiquitylation of other hsp90-
chaperoned proteins (5, 6), we wondered if CHIP could act as an
ubiquitin ligase for nNOS. In the current study, we have shown
that overexpression of CHIP causes the enhanced proteasomal
degradation of nNOS. Treatment with lactacystin, a selective
inhibitor of the proteasome, attenuates the loss of nNOS
caused by CHIP and leads to the accumulation of nNOS-Ub
conjugates. Under these conditions, the nNOS in cell cytosols is
found associated with CHIP. Moreover, in studies with the use
of an in vitro ubiquitylating system containing purified nNOS
and ubiquitin ligase enzymes, CHIP increases the amount of
nNOS-Ub conjugates. We also show here that hsp70, in the
presence of hsp40, greatly facilitates nNOS-ubiquitin conjuga-
tion in vitro. Our preparation of nNOS has substantial
amounts of insect hsp70, which could not be removed, and thus
the absolute requirement for hsp70 could not be tested. None-
theless, the addition of exogenous hsp70 greatly increases the
number of nNOS-ubiquitin conjugates. Thus, it is clear that
CHIP acts in concert with hsp70 and hsp40 to enhance the
ubiquitylation of nNOS, consistent with the established role of
CHIP as a chaperone-dependent E3-ubiquitin ligase.
Ubiquitylation and proteasomal degradation is a critical
component of protein quality control in cells. How proteins are
targeted for ubiquitylation and degradation is fundamental to
FIG. 3. Radicicol and CHIP enhance
the accumulation of detergent-resis-
tant nNOS protein. HEK293T cells
were transfected with nNOS (0.5 g) and
CHIP and then treated with () or with-
out () 20 M radicicol for 24 h. A, the
amount of CHIP cDNA used for transfec-
tion is indicated in g of cDNA. The sol-
uble and insoluble fractions were pre-
pared and Western blotted for nNOS,
CHIP, and tubulin. B, the band corre-
sponding to nNOS in the soluble fraction
from A was analyzed by laser densitome-
try. The effect of CHIP transfection on
nNOS levels without radicicol (open cir-
cles) or with radicicol (closed circles) is
plotted. The values are the mean  S.E.
(n  3). C, the band corresponding to
nNOS in the insoluble fraction from A
was analyzed by laser densitometry. The
effect of CHIP transfection on nNOS lev-
els without radicicol (open circles) or with
radicicol (closed circles) is plotted. The
values are the mean  S.E. (n  3).
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understanding the control of the cellular protein triage machin-
ery. It is widely thought that the E3 ubiquitin ligases select
target proteins for ubiquitylation and thus commit the target
protein to proteasomal degradation. CHIP is not only an E3
ligase but is also a co-chaperone for hsp90 and hsp70, and thus
CHIP has been proposed to play a role in protein triage deci-
sions through chaperones (6). CHIP has been described to act
via hsp70, hsp90, or a combination of the two chaperones (6–8,
10). The exact mechanism of how this occurs is not known.
CHIP is known to inhibit the hsp90-dependent binding of
steroid to the glucocorticoid receptor and decrease p23 bound to
the glucocorticoid receptorhsp90 heterocomplex (7). It was pro-
posed that this remodeling of the hsp90 heterocomplex explains
the enhanced ubiquitylation of the glucocorticoid receptor caused
by CHIP. Another proposed mechanism is the inhibition of hsp90
in a manner similar to ansamycin drugs, which bind to the ATP
binding site of hsp90 (6). The inhibition of hsp90 by ansamycin
drugs and the enhanced proteasomal degradation of the target
protein are some of the most convenient and commonly used
indicators of an hsp90 client protein. Thus, the inhibition of
hsp90 would explain the decreased levels of target protein caused
by CHIP. However, in studies with purified proteins, the ubiqui-
FIG. 4. CHIP increases ubiquitylation of nNOS proteins in HEK293T cells. HEK293T cells (10-cm dishes) were transfected for 28 h with
His-HA-ubiquitin and nNOS in the presence or absence of CHIP. The cells were then treated with 10 M lactacystin or water vehicle for another
20 h before lysis. A, the soluble fraction was prepared from the cells and used for immunoprecipitation with non-immune (NI) or an anti-nNOS (IP)
antibody followed by Western blot analysis with anti-ubiquitin (top panel), anti-nNOS (middle panel), and anti-CHIP (bottom panel) antibodies.
The data are representative of three identical experiments. B, the soluble fraction was used for immunoprecipitation with non-immune or an
anti-ubiquitin (IP) antibody, followed by Western blot analysis with anti-nNOS antibody. The data are representative of three identical
experiments.
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tylation of heat-denatured luciferase by CHIP is enhanced when
purified hsp90 is added, suggesting a direct role of hsp90 in the
ubiquitylation process (10).
We raise here the possibility that hsp70 directly mediates
protein triage decisions by recognition of nNOS and recruiting
an ubiquitin ligase machinery that involves CHIP. Bercovich et
al. (20) first described the requirement of hsp70 for ubiquitin-
dependent degradation of actin, -crystallin, glyceraldehyde-3-
phosphate dehydrogenase, -lactalbumin, and histone H2A.
These authors concluded that hsp70 was needed for ubiquitin
conjugation to occur but that hsp70 was not an E3-ubiquitin
ligase. Consistent with this view, the cystic fibrosis transmem-
brane conductance regulator protein is ubiquitylated by CHIP
and hsp70 but not hsp90 (8). Indeed heat-denatured luciferase
is ubiquitylated by CHIP in the presence of hsp70 in an in vitro
system consisting of purified proteins (10). Recently it was
shown that Parkin, an E3 ubiquitin ligase, also associates with
hsp70 and enhances ubiquitylation (21).
At any time, only a small percentage (1%) of nNOS is found
in the ubiquitylated state, and the ubiquitylated products are
thought to represent protein in a non-native conformation. It
makes sense that hsp70 makes the triage decision to proceed in
the direction of client protein degradation versus stabilization.
In the assembly of hsp90 heterocomplexes, the first step is an
ATP-dependent interaction with hsp70 and hsp40 to form a
“primed” client proteinhsp70 complex that then binds hsp90 in
a second ATP-dependent step to form the client proteinhsp90
heterocomplex (4). When the client protein is bound by hsp90,
it is stabilized, and inhibition of hsp90 binding by geldanamy-
cin or radicicol uniformly results in client protein destabiliza-
tion, manifest as degradation via the ubiquitin-proteasomal
pathway (22). In the early stages of protein damage and un-
folding, hydrophobic regions to which hsp70 can bind are ex-
posed. In this case, instead of forming a “primed” complex that
can interact with hsp90 and be stabilized, binding of CHIP to
the TPR acceptor site on the client protein-bound hsp70 can
lead to ubiquitylation and ultimately degradation as shown
here with nNOS.
Because of the dynamic nature of the interaction of hsp90
and hsp70 with nNOS (3, 23), we are unable to test in detail the
relative roles of these chaperones in ubiquitylation and degra-
dation of nNOS, specifically by the CHIP-chaperone-nNOS het-
erocomplexes. However, we intend to pursue this line of inves-
tigation with the glucocorticoid receptor, where much more
stable heterocomplexes with hsp90 and hsp70 can be formed in
stepwise fashion using a purified five-protein assembly system.
FIG. 5. CHIP increases ubiquityla-
tion of nNOS in an in vitro system
containing purified proteins. A, puri-
fied nNOS was treated in reaction mix-
ture containing purified E1 ubiquitin-ac-
tivating enzyme, E2 conjugating enzyme,
and GST-Ub. As indicated, some of the
samples contained purified CHIP, and
some of the nNOS samples were pre-
treated with hsp70 and hsp40. The sam-
ples were Western blotted by probing
with anti-nNOS IgG (left panel) or anti-
GST IgG (right panel), and higher molec-
ular mass Ub-conjugates of nNOS were
visualized. The data are representative of
six similar experiments. B, the purified
nNOS preparation contains insect hsp70.
Samples of purified nNOS were resolved
by SDS-PAGE and immunoblotted with
an antibody that reacts with insect hsp70.
Lane 1, 0.2 g of purified rabbit hsp70;
lane 2, 1.0 g of nNOS; lane 3, 2.0 g of
nNOS; lane 4, 3.0 g of nNOS; lane 5, 0.1
g of purified rabbit hsp70. The immuno-
blots were performed four times.
CHIP and Neuronal NO Synthase52976
This can be coupled with the purified ubiquitylation system
used here to determine whether hsp70, hsp90, or both can
direct CHIP-dependent ubiquitylation of a client protein.
Acknowledgments—We thank Solomon Snyder and Yi Sun for pro-
viding cDNA used in this work.
REFERENCES
1. Osawa, Y., Lowe, E. R., Everett, A. C., Dunbar, A. Y., and Billecke, S. S. (2003)
J. Pharmacol. Exp. Ther. 304, 1–5
2. Noguchi, S., Jianmongkol, S., Bender, A. T., Kamada, Y., Demady, D. R., and
Osawa, Y. (2000) J. Biol. Chem. 275, 2376–2380
3. Bender, A. T., Silverstein, A. M., Demady, D. R., Kanelakis, K. C., Noguchi, S.,
Pratt, W. B., and Osawa, Y. (1999) J. Biol. Chem. 274, 1472–1478
4. Pratt, W. B., and Toft, D. O. (2003) Exp. Biol. Med. 228, 111–133
5. Ballinger, C. A., Connell, P., Wu, Y., Hu, Z., Thompson, L. J., Yin, L. Y., and
Patterson, C. (1999) Mol. Cell. Biol. 19, 4535–4545
6. Cyr, D. M., Hohfeld, J., and Patterson, C. (2002) Trends Biochem. Sci. 27,
368–375
7. Connell, P., Ballinger, C. A., Jiang, J., Wu, Y., Thompson, L. J., Hohfeld, J.,
and Patterson, C. (2001) Nat. Cell Biol. 3, 93–96
8. Meacham, G. C., Patterson, C., Zhang, W., Younger, J. M., and Cyr, D. M.
(2001) Nat. Cell Biol. 3, 100–105
9. Demand, J., Alberti, S., Patterson, C., and Hohfeld, J. (2001) Curr. Biol. 11,
1569–1577
10. Murata, S., Minami, Y., Minami, M., Chiba, T., and Tanaka, K. (2001) EMBO
Rep. 2, 1133–1138
11. Jiang, J., Cyr, D., Babbitt, R. W., Sessa, W. C., and Patterson, C. (2003) J. Biol.
Chem. 278, 49332–49341
12. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith,
J. A., and Struhl, K. (1993) Current Protocols in Molecular Biology, pp.
9.1.1–9.1.7, John Wiley & Sons, New York
13. Jiang, J., Ballinger, C. A., Wu, Y., Dai, Q., Cyr, D. M., Hohfeld, J., and
Patterson, C. (2001) J. Biol. Chem. 276, 42938–42944
14. Bender, A. T., Demady, D. R., and Osawa, Y. (2000) J. Biol. Chem. 275,
17407–17411
15. Dittmar, K. D., Hutchison, K. A., Owens-Grillo, J. K., and Pratt, W. B. (1996)
J. Biol. Chem. 271, 12833–12839
16. Dittmar, K. D., Banach, M., Galigniana, M. D., and Pratt, W. B. (1998) J. Biol.
Chem. 273, 7358–7366
17. Garcia-Mata, R., Gao, Y. S., and Sztul, E. (2002) Traffic 3, 388–396
18. Johnston, J. A., Ward, C. L., and Kopito, R. R. (1998) J. Cell Biol. 143,
1883–1898
19. Hermida-Matsumoto, M. L., Chock, P. B., Curran, T., and Yang, D. C. (1996)
J. Biol. Chem. 271, 4930–4936
20. Bercovich, B., Stancovski, I., Mayer, A., Blumenfeld, N., Laszlo, A., Schwartz,
A. L., and Ciechanover, A. (1997) J. Biol. Chem. 272, 9002–9010
21. Tsai, Y. C., Fishman, P. S., Thakor, N. V., and Oyler, G. A. (2003) J. Biol.
Chem. 278, 22044–22055
22. Isaacs, J. S., Xu, W., and Neckers, L. (2003) Cancer Cells 3, 213–217
23. Billecke, S. S., Draganov, D. I., Morishima, Y., Murphy, P. J., Dunbar, A. Y.,
Pratt, W. B., and Osawa, Y. (2004) J. Biol. Chem. 279, 30252–30258
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Western blot analysis with anti-nNOS, anti-hsp90, anti-hsp70, and anti-CHIP antibodies as indicated. The data are representative of two identical
experiments.
CHIP and Neuronal NO Synthase 52977
